Primary Hyperoxaluria Type 1
9
1
2
4
Key Insights
Highlights
Success Rate
80% trial completion
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 49/100
11.1%
1 terminated out of 9 trials
80.0%
-6.5% vs benchmark
22%
2 trials in Phase 3/4
50%
2 of 4 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 4 completed trials
Clinical Trials (9)
BONAPH1DE, A Prospective Observational Study of Patients With Primary Hyperoxaluria Type 1 (PH1)
Nedosiran in Pediatric Patients From Birth to 11 Years of Age With PH and Relatively Intact Renal Function
Safety & Efficacy of DCR-PHXC in Patients With PH1 and ESRD
A Study to Evaluate Lumasiran in Patients With Advanced Primary Hyperoxaluria Type 1
Early Check: Expanded Screening in Newborns
A Study of DCR-PH1 in Patients With Primary Hyperoxaluria Type 1 (PH1)
Evaluation of the Efficacy and Safety of Stiripentol in Patients 6 Years and Older With Primary Hyperoxaluria Type 1, 2 or 3
Proteomics of Primary Hyperoxaluria Type 1
IDENTIFICATION OF A MULTI-ANALYTE PROFILE FOR PRIMARY HYPEROXALURIA AND COMPARISON WITH HEALTHY SIBLINGS AND IDIOPATHIC HYPERCALCIURIA